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Education and debate
Achieving the millennium development goals for health
Evaluation of current strategies and future priorities for improving
health in developing countries
David B Evans, Stephen S Lim, Taghreed Adam, Tessa Tan-Torres Edejer, WHO Choosing Interventions that are Cost
Effective (CHOICE) Millennium Development Goals Team
This article is the last in a series examining the cost effectiveness of strategies to achieve the millennium development goals for
health
More resources are needed to enable developing countries to fund just the health interventions that are highly cost
effective. Evidence that existing money is being well spent may help this cause
Five years after the Millennium Declaration was signed, few of
the poorest countries in the world are on track to achieve the
millennium development goals for health.1 2 In September 2005,
heads of state renewed their commitment to these goals and to
finding the resources to achieve them. The needs are substantial.
An additional $73bn (£41bn; €60bn) in external aid will be
needed in 2006 alone for all the millennium development goals,
with about $18.5bn for health.3 In this series we have examined
whether the strategies adopted for using the available resources,
and those planned for future resources, are appropriate in view
of the disappointing progress, changing circumstances, and new
evidence.4–8 Here, we summarise the key findings for each of the
health conditions targeted by the goals and then take the
perspective of a policy maker trying to achieve all of them.
Analysis of simultaneous interventions
Our method of analysis used two innovations to ensure the
results had more relevance to practical policy decisions than tra-
ditional cost effectiveness analysis.3 9–12 Firstly, the cost effective-
ness of the existing use of resources could be evaluated at the
same time as the cost effectiveness of possible future courses of
action should new resources become available. Traditional cost
effectiveness analysis has usually considered only future use of
resources. Secondly, we incorporated interactions between costs
and effects of interventions that are undertaken simultaneously,
as they would be in practice. Previous studies have generally
assumed, mostly implicitly, that every intervention is imple-
mented in isolation from related activities.
Here we have analysed more synergies between concurrent
interventions than were included in the analyses for separate
health goals.4–8 For example, different interventions that would
be delivered as part of a basic obstetric package, often by the
same person during the same visit, had been analysed separately
in the maternal and neonatal health (tetanus toxoid),5 HIV and
AIDS (prevention of mother to child transmission),6 and malaria
(intermittent presumptive treatment with sulfadoxine-
pyrimethamine in pregnancy)7 analyses. Cost synergies between
tetanus toxoid and other interventions aimed at maternal and
neonatal health were included in that paper, but here we add
synergies resulting from common delivery platforms across all
the health goals.
The individual papers eliminated several interventions from
further consideration because they proved to be more costly,
with lower health benefits, than others (see table B on bmj.com)
The remaining interventions were classified in a way that is use-
ful for setting priorities across multiple health conditions. We
earlier argued that the uncertainty around estimates of costs and
health gains, especially when information must be taken from a
limited number of data points, precludes basing policy advice on
the point estimates of cost effectiveness.3 For policy purposes,
interventions should be compared in terms of order of
magnitude cost effectiveness bands. Within any band, individual
decision makers have a menu of interventions to choose from.
We deemed interventions to be highly cost effective if they cost
less than the gross domestic product per capita to avert each dis-
ability adjusted life years (DALY) and cost effective if each DALY
could be averted at a cost of between one and three times the
gross domestic product per capita. Other interventions are not
cost effective.13 This incorporates an element of affordability as
regions and countries with lower national income will have lower
cut-off points.
Recommended strategy changes for each goal
In some cases, we found current strategies and plans to be essen-
tially appropriate, while more opportunities to reallocate
resources existed in others (box . Significant reductions in mater-
nal and neonatal mortality require, for example, increased access
to clinic based services providing basic and emergency obstetric
and neonatal care, but also increased community based preven-
tion, including the encouragement of breastfeeding, support of
low birthweight babies, treatment of neonatal pneumonia, and
wider provision of tetanus toxoid. If no new resources are forth-
coming and substantial resources currently support relatively
high cost, low effect interventions (such as antibiotics for prema-
ture rupture of membranes) policy makers could consider
Members of the WHO-CHOICE millennium development goals team and
further details are on bmj.com
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reallocating current spending to the more cost effective
interventions.
Priority setting across health goals
Tables 1 and 2 classify interventions into the cost effectiveness
bands described above for the two regions Afr-E (countries in
sub-Saharan Africa with very high adult mortality and high child
mortality) and Sear-D (countries in South East Asia with high
adult and child mortality). Tables C and D on bmj.com gives
details of costs, effects, and cost effectiveness ratios.
Application of results
In practice, resources are never allocated according to formulaic
cost effectiveness rules described in text books—for example, by
choosing the most cost effective intervention, then the next most
cost effective, until all resources are used. This can sometimes
suggests that only prevention should take place, or only
treatment, but in reality mixes of interventions are generally
found. Our analysis suggests this is appropriate. The highly cost
effective group of interventions reported above includes a selec-
tion from each of the five goals in both regions, as well as mixes
of curative and preventive actions and of population and
individually focused activities. This is true even if the threshold
for highly cost effective interventions is reduced to $Int100 per
DALY averted.
Both regions have so much unmet need and so many under-
used interventions that the opportunities for reallocating
resources are limited. Purely on cost effectiveness grounds, how-
ever, priority should clearly be given to highly cost effective
interventions rather than activities such as second line antiretro-
viral therapy for AIDS and provision of supplementary food for
children in Afr-E.More could be achieved if these resources were
reallocated to any of the under-used, highly cost effective group.
A similar picture unfolds in Sear-D. Attention should be focused
on scaling up interventions that are highly cost effective rather
than expanding second line antiretroviral therapy (which is just
over the threshold for cost effective interventions), antenatal
steroids for preterm births, and provision of supplementary food
for children.
Both regions have a relatively large set of highly cost effective
interventions, offering considerable flexibility to adapt packages
to particular contexts. The relative size of the highly cost effective
group reflects the unmet needs but also the fact that the millen-
nium development goals were well chosen and need to be better
funded. Many more interventions would fall outside the highly
cost effective group had our analysis included conditions outside
the goals, and it is here that greater potential to reallocate
resources toward the goals may be found.
Validity of cost effectiveness
We accept that in practice, considerations other than cost
effectiveness do, and should, influence decisions on resource
allocation. Important debate continues about the appropriate-
ness of using cost effectiveness analysis to drive decisions in
health. For example, the technique focuses only on the health
gains associated with different uses of resources and does not
incorporate other effects of concern to society. This may be par-
ticularly relevant to antiretroviral treatment for HIV and AIDS,
which keeps health workers and school teachers in their posts
and could, at the limit, prevent a possible break down of
society.14 15 These benefits cannot be captured in terms of DALYs.
Use of cost effectiveness analysis also raises several ethical issues,
particularly the fact that equity is not explicitly incorporated.15 16
Policy makers, however, cannot escape from the unfortunate
fact that the resources available are insufficient even to
implement all the interventions designated in this paper as
highly cost effective, and it is not yet clear that the additional
resources required to reach the millennium development goals
will be found. In such cases, informed decisions about how to
allocate the available resources require knowledge of the likely
Modifications to current strategies to meet millennium
development goals
Maternal and neonatal health
Higher priority should be given to increasing access to clinical
facility based services providing basic and emergency obstetric
and neonatal care
Insufficient coverage of a highly cost effective preventive
interventions, including community support for breastfeeding
mothers and low birthweight babies, treatment of neonatal
pneumonia, provision of tetanus toxoid, and screening mothers
for syphilis, bacteruria, and pre-eclampsia
Lower priority should be given to high cost, low effect
interventions such as antibiotics for preterm rupture of
membranes and antenatal steroids for preterm births (in Sear-D)
Child health
Increased efforts to fortify processed food staples with multiple
micronutrients; especially vitamin A and zinc
Current focus on personal interventions is appropriate: measles
immunisation, case management of pneumonia, oral rehydration
therapy
If more resources are available, vitamin A and zinc
supplementation could replace fortification
When resources are very limited, these interventions should be
given higher priority than higher cost, less effective alternatives
such as
Research on more cost effective health interventions for
malnutrition is urgently needed
HIV and AIDS
Prevention strategies based on treatment of sexually transmitted
infections, educating sex workers, and some types of mass media
messages are highly cost effective
School based education has uncertain effectiveness and is not
highly cost effective in Sear-D.
Treatment with first line antiretrovirals is at least as cost effective
as some of the well known preventive interventions, such as
voluntary counselling and testing
Malaria
In most countries of sub-Saharan Africa serious consideration
should be given to improved case management with artemisinin
based combination treatments
This should be integrated with use of insecticide treated bed nets
or indoor residual spraying
Where these are being successfully implemented, intermittent
presumptive treatment of pregnant women can bring an
important additional health benefit
Greater effort should be given to increasing coverage of malaria
interventions
Tuberculosis
Effective treatment of infectious (sputum smear positive) cases is
the first priority, including for patients coinfected with HIV
Improving case finding should now also be given high priority
Once these elements are in place, treatment should be extended
to patients who are less infectious (sputum smear negative) and
with multidrug resistant strains
Antiretroviral therapy should be offered in conjunction with
tuberculosis treatment for patients infected with HIV
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effect on population health of different courses of action. With-
out this knowledge, decisions could be made to improve the
health of a few people by a small amount at the expense of
improving the health of more people by a larger amount, some-
thing that neither the proponents nor opponents of cost
effectiveness analysis would want.
Many grounds may exist to justify implementing the
interventions we have identified as less cost effective. For exam-
ple interventions, such as feeding malnourished infants or man-
agement of obstructed labour, target a group in society with
particularly poor health. Although this is perfectly legitimate, we
argue that decision makers cannot make an informed decision
without information on the opportunities to improve population
health that are forgone elsewhere. Our results represent the best
evidence currently available and show difficult trade-offs may
need to be made. Another equally important message from our
Table 1 Interventions to achieve health millennium development goals in region Afr-E by order of cost effectiveness
Goal Intervention (coverage)
Highly cost effective*
Maternal and neonatal health Community based case management for neonatal pneumonia (95%)
HIV and AIDS Mass media campaign to promote safer sex (100%)
HIV and AIDS Peer education and treatment of sexually transmitted infections for sex workers (50%)
HIV and AIDS Peer education and treatment of sexually transmitted infections for sex workers (expanded to 80%)
HIV and AIDS Peer education and treatment of sexually transmitted infections for sex workers (expanded to 95%)
Tuberculosis Treatment of new smear-positive tuberculosis cases only under DOTS (50%)
Maternal and neonatal health Community newborn package (95%):
support for breastfeeding mothers and low birthweight babies
Tuberculosis Treatment of new cases of smear positive tuberculosis only under DOTS (expanded to 80%)
Malaria Case management of malaria with artemisinin based combination treatment (95%)
Tuberculosis Treatment of new cases of smear positive tuberculosis only under DOTS (expanded to 95%)
Under 5s Vitamin A fortification of food staple (95%)
Zinc fortification of food staple (95%)
Maternal and neonatal health Tetanus toxoid (95%)
HIV and AIDS Prevention of mother to child transmission (antenatal care coverage)
Maternal and neonatal health Screening for pre-eclampsia (95%)
Screening and treatment of asymptomatic bacteruria (95%)
Screening and treatment of syphilis (95%)
Under 5s Measles vaccination (80%)
Maternal and neonatal health Normal delivery by skilled attendant (95%)
Active management of the third stage of labour (95%)
Initial management of post-partum haemorrhage (95%)
Neonatal resuscitation (95%)
Maternal and neonatal health Treatment of severe pre-eclampsia and eclampsia (95%)
Malaria Insecticide treated bed nets (95%)
Under 5s Measles vaccination (expanded to 95%)
Maternal and neonatal health Facility based care of very low birthweight babies, severe neonatal infections, severe neonatal asphyxia, and neonatal jaundice
HIV and AIDS Treatment of sexually transmitted infections (current coverage)
Under 5s Case management for childhood pneumonia (80%)
Maternal and neonatal health Management of obstructed labour, breech presentation, and fetal distress (95%)
HIV and AIDS Treatment of sexually transmitted infections (expanded to antenatal care coverage)
Under 5s Vitamin A supplementation (80%, replaces fortification)
Zinc supplementation (80%, replaces fortification)
Tuberculosis Treatment of smear negative tuberculosis under DOTS (95%)
Under 5s Oral rehydration therapy for diarrhoea (80%)
Maternal and neonatal health Antenatal steroids for preterm births (95%)
Malaria Indoor residual spraying (95%)
Tuberculosis Treatment of multi-drug resistant tuberculosis under DOTS-Plus (95%)
Maternal and neonatal health Management of maternal sepsis (95%)
Malaria Intermittent presumptive treatment with sulfadoxine-pyrimethamine during pregnancy (95%)
Maternal and neonatal health Antibiotics for pre-term premature rupture of membranes (95%)
HIV and AIDS Voluntary counselling and testing (95%)
Maternal and neonatal health Referral care for severe post-partum haemorrhage
Under 5s Vitamin A supplementation (expanded to 95%)
Case management for childhood pneumonia (expanded to 95%)
Zinc supplementation (expanded to 95%)
Oral rehydration therapy for diarrhoea (expanded to 95%)
HIV and AIDS Treatment of sexually transmitted infections (expanded to 95%)
HIV and AIDS Antiretroviral therapy: no intensive monitoring, first-line drugs only (95%)
HIV and AIDS School based education on safer sex (95%)
HIV and AIDS Antiretroviral therapy: intensive monitoring, first-line drugs only (95%)
Not cost effective†
HIV and AIDS Antiretroviral therapy: intensive monitoring, first and second line drugs (95%)
Under 5s Improved complementary feeding, growth monitoring and promotion (95%)
*Incremental cost effectiveness ratio ≤$Int1576 (see table A on bmj.com for conversion factor).
†Incremental cost effectiveness ratio>$Int4728.
Note: No interventions fall into the cost-effective band (incremental cost effectiveness ratio >$Int1576 and ≤$Int4728) for Afr-E
Education and debate
BMJ Online First bmj.com page 3 of 5
 on 15 November 2007 bmj.comDownloaded from 
results is the need to redouble efforts to raise additional funds for
health in poor countries. Our experience with economists in
ministries other than health is that it is much easier to convince
them of the need for funds if both additional and existing funds
are well spent. We hope that this series contributes to not only
improving population health with the available resources but to
raising more funds for health as well.
We thank Megha Mukim, Jason Lee and Marilyn Vogel for help with refer-
encing.
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Table 2 Interventions to achieve health millennium development goals in region Sear-D by order of cost effectiveness
Goal Intervention (coverage)
Highly cost effective*
HIV and AIDS Peer education and treatment of sexually transmitted infections for sex workers (50%)
HIV and AIDS Peer education and treatment of sexually transmitted infections for sex workers (expanded to 80%)
HIV and AIDS Peer education and treatment of sexually transmitted infections for sex workers (expanded to 95%)
Maternal and neonatal health Community based support for breastfeeding mothers (50%)
Maternal and neonatal health Community based support for breastfeeding mothers (expanded to 80%)
Tuberculosis Treatment of new cases of smear positive tuberculosis only under DOTS (80%)
Maternal and neonatal health Community based support for breastfeeding mothers (expanded to 95%)
Maternal and neonatal health Tetanus toxoid (80%)
Tuberculosis Treatment of new smear positive tuberculosis only under DOTS (expanded to 95%)
Maternal and neonatal health Tetanus toxoid (expanded to 95%)
Under 5s Zinc fortification of food staple (95%)
Maternal and neonatal health Community based support for low birthweight babies (95%)
HIV and AIDS Mass media campaign to promote safer sex (100%)
Tuberculosis Treatment of smear negative tuberculosis under DOTS (95%)
Under 5s Vitamin A fortification of food staple (95%)
Under 5s Case management for childhood pneumonia (80%)
Maternal and neonatal health Normal delivery by skilled attendant (95%)
Active management of third stage and initial treatment of post-partum haemorrhage (95%)
Under 5s Case management for childhood pneumonia (expanded to 80%)
Under 5s Measles vaccination (95%)
Maternal and neonatal health Screening for pre-eclampsia (95%)
Screening and treatment of asymptomatic bacteruria (95%)
HIV and AIDS Treatment of sexually transmitted infections (95%)
Maternal and neonatal health Community based case management for neonatal pneumonia (95%)
Under 5s Zinc supplementation (95%, replaces fortification)
Oral rehydration therapy for diarrhoea (95%)
Maternal and neonatal health Neonatal resuscitation (95%)
Treatment of severe pre-eclampsia and eclampsia (95%)
Tuberculosis Treatment of multi-drug resistant tuberculosis under DOTS-Plus (95%)
Maternal and neonatal health Referral care for severe post-partum haemorrhage (95%)
Maternal and neonatal health Management of maternal sepsis (95%)
HIV and AIDS Voluntary counselling and testing (95%)
Under 5s Vitamin A supplementation (95% replaces fortification)
HIV and AIDS Prevention of mother to child transmission (antental care coverage)
Maternal and neonatal health Facility based care of very low birthweight babies, severe neonatal infections, severe neonatal asphyxia, and neonatal jaundice (95%)
HIV and AIDS Screening and treatment of syphilis (95%)
Maternal and neonatal health Antiretroviral therapy: no intensive monitoring, first line drugs only (95%)
HIV and AIDS Antiretroviral therapy: intensive monitoring, first line drugs only (95%)
Cost effective†
HIV and AIDS School based education (95%)
Maternal and neonatal health Management of obstructed labour, breech presentation, and fetal distress (95%)
Maternal and neonatal health Antibiotics for preterm premature rupture of membranes (95%)
Not cost effective‡
HIV and AIDS Antiretroviral therapy: intensive monitoring, first and second line drugs (95%)
Maternal and neonatal health Antenatal steroids for preterm births (95%)
Under 5s Improved complementary feeding, monitoring and promotion of growth (95%)
*Incremental cost effectiveness ratio ≤$Int1449 (see table A on bmj.com for conversion factor).
†Incremental cost effectiveness ratio >$Int1449 and ≤$Int4347.
‡Incremental cost effectiveness ratio>$Int4347.
Summary points
Separate analysis for millennium health goals showed how
resources could be used better
Combined analysis for all the goals highlights the priorities
for policy makers with responsibility for all aspects
Many more interventions than countries can afford to fund
are classified as highly cost effective
More resources urgently need to be made available
Education and debate
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on the implications of their papers for the final summary. SSL put the
results together for tables and figures. The opinions expressed in the paper
are those of the authors and do not necessarily represent the views of the
organisations they represent
Competing interests: None declared.
1 Nanda G, Switlick K, Lule E. Accelerating progress towards achieving the MDG to improve
maternal health: a collection of promising approaches. Washington, DC: International Bank
for Reconstruction and Development, World Bank, 2005.
2 Evans DB, Adam T, Tan-Torres Edejer T, Lim SS, Cassels A, Evans TG, et al. Achieving
the millennium development goals for health: time to reassess strategies for improving
health in developing countries? BMJ 2005;3311133-6.
3 Evans D, Tan-Torres Edejer T, Adam T, Lim S, the WHO-CHOICE MDG team. Achiev-
ing the millennium development goals for health: methods to assess the costs and
health effects of interventions for improving health in developing countries. BMJ
2005;331:1137-40.
4 Tan-Torres Edejer T, Aikins M, Black R, Wolfson L, Hutubessy R, Evans DB. Achieving
the millennium development goals for health: cost effectiveness analysis of strategies
for child health in developing countries. BMJ Nov 10; epub ahead of print
(doi:10.1136/bmj.38652.550278.7C).
5 Adam T, Lim SS, Mehta S, Bhutta ZA, Fogstad H,Mathai M, et al. Achieving the millen-
nium development goals for health: cost effectiveness analysis of strategies for mater-
nal and neonatal health in developing countries. BMJ 2005;331:1107-10.
6 Hogan D, Baltussen R, Hayashi C, Lauer J, Salomon J. Achieving the millennium devel-
opment goals for health: cost effectiveness analysis of strategies to combat HIV/AIDS
in developing countries. BMJ Nov 10; epub ahead of print (doi:10.1136/
bmj.38643.368692.68).
7 Morel C, Lauer J, Evans DB. Achieving the millennium development goals for health:
cost effectiveness analysis of strategies to combat malaria in developing countries. BMJ
Nov 10; epub ahead of print (doi:10.1136/bmj.38639.702384.AE).
8 Baltussen R, Floyd K, Dye C. Achieving the millennium development goals for health:
cost effectiveness analysis of strategies for tuberculosis control in developing countries.
BMJ Nov 10; epub ahead of print (doi:10.1136/bmj.38645.660093.68).
9 Adam T, Evans DB, Murray CJL. Econometric estimation of country specific hospital
costs. Cost Eff Resour Alloc 2003;1:3.
10 Johns B, Baltussen R, Hutubessy RCW. Programme costs in the economic evaluation of
health interventions. Cost Eff Resour Alloc 2003;1:1.
11 Lauer JA, Rohrich K, Wirth H, Charette C, Gribble S, Murray CJL. PopMod: a longitu-
dinal population model with two interacting disease states. Cost Eff Resour Alloc
2003;1:6.
12 Baltussen RM, Adam T, Tan Torres T, Hutubessy RC, Acharya A, Evans DB, Murray CJ.
Generalized cost-effectiveness analysis: a guide. Geneva:WHO, 2003. http://www3.who.int/
whosis/cea/background_documents/pdf/guidelines.pdf (accessed 27 Oct 2005).
13 Commission on Macroeconomics and Health. Macroeconomics and health: investing in
health for economic development. Boston: Center for International Development at
Harvard University, 2001. www.cid.harvard.edu/cidcmh/CMHReport.pdf (accessed 17
Oct 2005).
14 Evans DB. Communicable diseases: alternative perspectives. In Lomborg B, ed. Global
crises, global solutions. Cambridge: Cambridge University Press, 2004:115-23.
15 Yong KJ, Shakow A, Mate K, Vanderwarker C, Gupta R, Farmer P. Limited good and
limited vision: multidrug-resistant tuberculosis and global health policy. Soc Sci Med
2005;61:847-59.
16 Brock DW. Priority to the worst off in health care resource prioritization. In: Battin M,
Rhodes R, Silvers A, eds. Health care and social justice. New York: Oxford University
Press, 2003.
(Accepted 12 October 2005)
doi 10.1136/bmj.38658.675243.94
Health Systems Financing, Evidence and Information for Policy, World Health
Organization, Geneva, Switzerland
David B Evans director
School of Population Health, University of Queensland, Australia
Stephen S Lim research fellow
Health Systems Financing, Evidence and Information for Policy, World Health
Organization
Taghreed Adam health economist
Costs, Effectiveness, Expenditure and Priority Setting, World Health Organization
Tessa Tan-Torres Edejer coordinator
Correspondence to: David B Evans evansd@who.int
Education and debate
BMJ Online First bmj.com page 5 of 5
 on 15 November 2007 bmj.comDownloaded from 
